Department of Hematology and Oncology, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
Curr Opin Immunol. 2011 Oct;23(5):679-84. doi: 10.1016/j.coi.2011.06.006. Epub 2011 Jul 27.
The adoptive transfer of donor-type CD4(+)CD25(+)FOXP3(+) regulatory T cells (Treg) protects from graft-versus-host disease in murine bone marrow transplantation models. Results from first clinical trials exploring such strategies have recently been presented and seem to confirm the efficacy of Treg for the prevention of this severe complication after allogeneic stem cell transplantation. Further improvements in Treg isolation and in vitro expansion technologies will facilitate the broader exploration of Treg therapies, for example, for the treatment of ongoing graft-versus-host disease or the prevention of graft rejection after solid organ transplantation.
供体来源的 CD4(+)CD25(+)FOXP3(+)调节性 T 细胞（Treg）过继转移可防止骨髓移植模型中的移植物抗宿主病。最近提出了探索此类策略的首次临床试验结果，这些结果似乎证实了 Treg 预防异基因干细胞移植后这种严重并发症的疗效。Treg 分离和体外扩增技术的进一步改进将促进 Treg 治疗的更广泛探索，例如，用于治疗正在进行的移植物抗宿主病或预防实体器官移植后的移植物排斥。
